( Toronto:TH )

News from Theratechnologies Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 04, 2017, 07:00 ET Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced 48-week efficacy and safety results for ibalizumab in patients infected with...


Jul 24, 2017, 07:30 ET Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that results on HIV susceptibility to ibalizumab from the Phase IIb trial,...


May 03, 2017, 21:03 ET Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that its partner, TaiMed Biologics, Inc., has completed the submission of a...


Feb 15, 2017, 19:00 ET Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that pharmacokinetics (PK) and pharmacodynamics (PD) data comparing the...


Feb 14, 2017, 19:00 ET Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that additional secondary efficacy and safety endpoint results from the...


Nov 10, 2016, 07:00 ET Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it has been notified by its partner, TaiMed Biologics, Inc., of the...


Oct 28, 2016, 10:00 ET Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016™

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced additional results related to the primary endpoint of the ibalizumab Phase III...


Jul 05, 2005, 01:00 ET Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy

MONTREAL, July 5 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) announced today that on June 30 a patient in Atlanta, Georgia, became the...


Mar 31, 2005, 00:00 ET Green Light for ThGRF in Phase III

MONTREAL, March 31 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) reports on a positive meeting with the Food and Drug Administration (FDA)...


Mar 30, 2005, 00:00 ET Media Advisory - Theratechnologies to Report on FDA Meeting for ThGRF

MONTREAL, March 30 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) advises that it will be reporting on a meeting held today with the Food...


Mar 23, 2005, 00:00 ET Theratechnologies: GLP-1 Results

MONTREAL, March 23 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) announced today good safety results testing TH0318, a glucagon-like...


Nov 30, 2004, 00:00 ET Theratechnologies Business Update

MONTREAL, Nov. 30 /PRNewswire-FirstCall/ - Theratechnologies' (TSX: TH) President and Chief Executive Officer, Mr. Yves Rosconi, today provided a...


Aug 26, 2004, 01:00 ET Theratechnologies presents results from its HIV-associated lipodystrophy Phase II study on ThGRF at the 12th International Congress of Endocrinology

MONTREAL, Aug. 26 /PRNewswire-FirstCall/ - Theratechnologies (TSX :TH) announced today that results of its Phase II clinical trial on ThGRF in...


Jul 07, 2004, 01:00 ET Theratechnologies: Celmed BioSciences completes NewBiotics acquisition

MONTREAL, July 7 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) announced today that Celmed BioSciences has completed the acquisition of...


Jun 07, 2004, 01:00 ET Celmed BioSciences, a subsidiary of Theratechnologies, to acquire NewBiotics

MONTREAL, June 7 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) announced today that its subsidiary, Celmed BioSciences, is acquiring...


May 03, 2004, 01:00 ET Theratechnologies: Preliminary Phase I Results for ThPTH in Osteoporosis - First human testing combining PTH and ALZA's Macroflux(R) transdermal technology

MONTREAL, May 3rd /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) today announced positive preliminary results of a Phase I clinical study...


Apr 15, 2004, 01:00 ET Theratechnologies Reports Phase II Results for ThGRF in HIV associated Lipodystrophy

MONTREAL, April 15 /PRNewswire-FirstCall/ - Theratechnologies (TSX:TH) today announced exciting results for its Phase II clinical trial, testing...


Apr 14, 2004, 01:00 ET Market Advisory: Theratechnologies to disclose Phase II results for ThGRF in HIV-lipodystrophy

MONTREAL, April 14 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) will disclose the results of its Phase II trial on HIV-related...


Feb 13, 2004, 00:00 ET Theratechnologies to host webcast Tuesday, February 17, 2003 at 4:30 p.m. - Management to discuss fourth quarter and year-end results for 2003

MONTREAL, Feb. 13 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) today announced that it will host a conference call on Tuesday, February...


Dec 11, 2003, 00:00 ET Theratechnologies completes enrolment for Phase II trial in HIV-related lipodystrophy

MONTREAL, Dec. 11 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) announced today that it has completed enrolment for its Phase II clinical...


Dec 09, 2003, 00:00 ET Theratechnologies reports results for Phase II trial in wasting secondary to hip fracture surgery

MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) announced today that its drug candidate, ThGRF, did not demonstrate...


Dec 08, 2003, 00:00 ET Market Advisory: Theratechnologies to disclose Phase II results in hip fracture wasting for ThGRF

MONTREAL, Dec. 8 /PRNewswire-FirstCall/ - Theratechnologies (TSX:TH) will disclose the results of its Phase II trial on wasting secondary to hip...


Nov 10, 2003, 00:00 ET Theratechnologies to present at CIBC World Markets HealthCare Conference in New York

MONTREAL, Nov. 10 /PRNewswire-FirstCall/ - Theratechnologies (TSX:TH) announces that Mr. Luc Tanguay, President and Chief Executive Officer, and...


Oct 21, 2003, 01:00 ET Theratechnologies: ThGRF a potential treatment for patients with wasting associated with COPD

MONTREAL, Oct. 21 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) today announced preliminary results for a Phase II study testing ThGRF,...


Oct 20, 2003, 01:00 ET Market Advisory: Theratechnologies to disclose Phase II results in COPD wasting for its lead compound, ThGRF

MONTREAL, Oct. 20 /PRNewswire-FirstCall/ - Theratechnologies (TSX:TH) will disclose the results of its Phase II trial on wasting secondary to...